Multiple Sclerosis Trial, Recruiting NCT06455332 Sponsor: University Hospital, Lille Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT06455332
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 55 years old
  • You have had a first episode of neurological symptoms (called a "clinically isolated syndrome") within the last 6 months
  • Your brain or spinal cord MRI shows at least two areas of concern that may suggest MS, OR your spinal fluid tests show specific proteins called oligoclonal bands
  • You are willing and able to sign a written consent form to participate

Who may not be able to join:

  • You have a condition that could affect the accuracy of eye-related scans, such as diabetes, glaucoma, a retinal disease, or a very strong glasses prescription (over 6 dioptres)
  • You have previously had MS relapses (this would be your first-ever episode)
  • You have had severe spinal cord inflammation affecting a long section of the spine (more than 3 vertebral segments)
  • You have had inflammation of both optic nerves (both eyes) but without the expected MS-related changes on MRI
  • You have a reason why you cannot have an MRI scan or receive a contrast dye injection called gadolinium (confirm with trial site)
  • You are currently pregnant or breastfeeding
  • You are unable to give your own informed consent to participate

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0320444145

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
17 July 2025
Est. completion
1 July 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Optic nerve involvement defined by occurrence of a recent clinical episode of ON; Asymptomatic optic nerve involvement defined by MRI (detection of an optic nerve T2 hypersignal); Risk of a new clinical relapse will be assessed by the occurrence and time to onset of a second MS clinical relapse; Asymptomatic optic nerve involvement defined by OCT (GCIPL-IETD,3pm); Risk of a new clinical relapse will be assessed by the occurrence and time to onset of a CDMS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov